Amneal Pharmaceuticals’ stock soars 14% premarket after company offers upbeat Q1 guidance

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

Amneal Pharmaceuticals Inc.’s stock soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter...

Amneal Pharmaceuticals Inc.’s stock AMRX soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter guidance that topped consensus estimates. Bridgewater, N.J.-based Amneal said it expects revenue for the quarter to range from $550 million to $560 million, up about 12% from the year-earlier quarter and above the $529 million FactSet consensus.

Bridgewater, N.J.-based Amneal said it expects revenue for the quarter to range from $550 million to $560 million, up about 12% from the year-earlier quarter and above the $529 million FactSet consensus. The company is expecting its pretax loss to range from $10 million to breakeven, an improvement of about 50% from a year ago. The company’s long-term debt is expected to stand at $2.692 billion at quarter-end, while cash is expected to stand at $151 million, resulting in net debt of $2.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 3. in BE

Belgique Dernières Nouvelles, Belgique Actualités